APhA ENDORSES FULL BAN ON DRUG SAMPLING
APhA ENDORSES FULL BAN ON DRUG SAMPLING as one of three resolutions adopted at a May 25 board meeting. Approving a motion to support "legislation that would ban drug product sampling," the pharmacy association is setting the foundation for any attempts to raise the topic of sampling as part of the larger Capitol Hill consideration of health care reform proposals. Sen. Kassebaum (R- Kan.) and Rep. Brewster (D-Okla.) remain interested in introducing bills to ban sampling after Congress returns from the Memorial Day recess.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth